MedTrace Logo

Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients

NCT04912687 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 581

Last updated 2026-03-06

No results posted yet for this study

Summary

Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid biopsy and tissue analyses.

Conditions

  • Non Small Cell Lung Cancer
  • Advanced Solid Tumor

Interventions

DIAGNOSTIC_TEST

EGFR gene mutation analysis on liquid biopsy

Blood samples will be collected at inclusion for plasma DNA collection and analysis.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Institut Bergonié

    lead OTHER

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2026-01-17
Completion
2026-01-17

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04912687 on ClinicalTrials.gov